ARTICLE | Clinical News

ALX-0171: Ph IIb RESPIRE started

January 13, 2017 4:14 PM UTC

Ablynx began the double-blind, placebo-controlled, international Phase IIb RESPIRE trial to evaluate 3, 6 and 9 mg/kg inhaled ALX-0171 once daily for 3 days in about 180 hospitalized infants ages 1-24...

BCIQ Company Profiles

Ablynx N.V.

BCIQ Target Profiles

RSV F protein